TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Vor Bio
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Telitacicept demonstrated a 55% reduction in proteinuria and statistically significant improvements in kidney function during a Phase 3 clinical trial for IgA Nephropathy in China, with a favorable safety profile.

Insights
SCS   neutral

The company is being acquired, with ongoing negotiations and procedural steps being taken to facilitate the merger


VOR   positive

Successfully achieved primary and secondary endpoints in clinical trial, demonstrating potential therapeutic effectiveness of telitacicept